In light of the pause in commercialization of EMFLAZA™ (deflazacort) by Marathon Pharmaceuticals earlier this week, PPMD recommends that Marathon seek input from a broad array of stakeholders including Duchenne clinicians, health insurance plans, pharmacy benefit managers, and Duchenne advocacy groups.

These inputs should be evidence-based to the greatest extent possible so that Marathon can evaluate the valuation model and impact on pricing.

We further suggest that Marathon should be transparent about the methodology used in their re-evaluation of a launch price for EMFLAZA – and specifically in identifying any impacts of a revised launch price on patient assistance programs, future research, and their continued engagement in the Duchenne community.

We look forward to a response from Marathon about their next steps and will continue to keep you informed.

Related links

• Marathon Pharmaceuticals Pauses Commercialization of EMFLAZA™
• Deflazacort Approved in the U.S. for Duchenne
• EMFLAZA.com